Default

Allergy and immunology

Anaesthesia

Basic research

Cardiovascular medicine

Complementary medicine and alternative therapies

Critical care / intensive care

Dentistry / oral medicine

Dermatology

Emergency medicine

Endocrinology

Epidemiology

Ethics

Evidence-based medicine

Gastroenterology

Genetics

Geriatric medicine / aging

Haematology / blood transfusion

Health economics

Health policy

History of medicine

Infectious diseases

Internal medicine

Laboratory medicine

Medical education

Medical informatics

Neurology

Nursing

Nutrition and metabolism

Obstetrics and gynaecology

Occupational and environmental medicine

Oncology

Ophthalmology

Organisation of health care

Otolaryngology / head and neck surgery

Paediatrics

Palliative care

Pathology

Patient-physician relationship

Pharmacology and therapeutics

Primary care, family medicine

Psychiatry and psychotherapy

Psychosomatics

Public health

Quality of care

Radiology

Rehabilitation medicine

Renal medicine

Respiratory medicine

Rheumatology

Sexual medicine

Sports medicine

Statistics and research methods

Surgery

Transplantation

Travel medicine

Urology

Ops! No article found. Reset filter

Management of bleeding events and invasive procedures in patients with haemophilia A without inhibitors treated with emicizumab

Review article: Medical guidelines
Fontana P, Alberio L, Albisetti M, Angelillo-Scherrer A, Asmis LM, Casini A, Gerber B, Graf L, Hegemann I, Korte W, Martinez M, Studt JD, Tsakiris DA, Wuillemin WA, Kremer Hovinga JA
Swiss Med Wkly. 2020;150:w20422

Based on the available literature and the experiences collected from adult and paediatric patients treated in Switzerland, the Working Party on Haemostasis of the Swiss Society of Haematology and the Swiss Haemophilia Network provides a practical guidance for the management of breakthrough bleeding events and surgery in patients with haemophilia A without inhibitors treated with emicizumab.

Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis

Review article: Medical guidelines
Schwotzer R, Flammer AJ, Gerull S, Pabst T, Arosio P, Averaimo M, Bacher VU, Bode P, Cavalli A, Concoluci A, Dirnhofer S, Djerbi N, Dobner SW, Fehr T, Garofalo M, Gaspert A, Heimgartner R, Hübers A, Jung HH, Kessler C, Knöpfel R, Laptseva N, Manka R, Mazzucchelli L, Meyer M, Mihaylova V, Monney P, Mylonas A, Nkoulou R, Pazhenkottil A, Pfister O, Rüfer A, Schmidt A, Seeger H, Stämpfli SF, Stirnimann G, Suter T, Théaudin M, Treglia G, Tzankov A, Vetter F, Zweier M, Gerber B
Swiss Med Wkly. 2020;150:w20364

These are the Swiss Amyloidosis Network recommendations which focus on diagnostic work-up and treatment of AL-amyloidosis. One aim of this meeting was to establish a consensus guideline regarding the diagnostic work-up and the treatment recommendations for systemic amyloidosis tailored to the Swiss health care system.

Supplementum 247: Swiss Hematology & Oncology Congress (SOHC)

Supplement
Swiss Med Wkly. 2020;150:w20411

Venous thromboembolism in COVID-19: systematic review of reported risks and current guidelines

Systematic review
Fontana P, Casini A, Robert-Ebadi H, Glauser F, Righini M, Blondon M
Swiss Med Wkly. 2020;150:w20301

Venous thromboembolism very commonly complicates the clinical course of inpatients with COVID-19, despite thromboprophylaxis. The risk appears highest among critically ill inpatients. Many questions remain unresolved, as delineated by the heterogeneity of national and international guidelines.

Recommendations on the use of anticoagulants for the treatment of patients with heparin-induced thrombocytopenia in Switzerland

Review article: Medical guidelines
Alberio L, Angelillo-Scherrer A, Asmis L, Casini A, Fontana P, Graf L, Hegemann I, Kremer Hovinga JA, Korte W, Lecompte T, Martinez M, Nagler M, Studt JD, Tsakiris DA, Wuillemin W
Swiss Med Wkly. 2020;150:w20210

Management of acute heparin-­induced thrombocytopenia currently involves cessation of heparin exposure, and inhibition of coagulation with an anticoagulant other than heparin.

Thromboprophylaxis and laboratory monitoring for in-hospital patients with COVID-19 - a Swiss consensus statement by the Working Party Hemostasis

Special article
Casini A, Alberio L, Angelillo-Scherrer A, Fontana P, Gerber B, Graf L, Hegemann I, Korte W, Kremer Hovinga JA, Lecompte T, Martinez M, Nagler M, Studt JD, Tsakiris D, Wuillemin W, Asmis L
Swiss Med Wkly. 2020;150:w20247

Based on the available literature and published recommendations from international societies, the Working Party on Hemostasis (Swiss Society of Hematology) has prepared recommendations for pharmacological thromboprophylaxis in COVID-19 patients in the acute setting.

Liquid biopsy in tissue-born lymphomas

Review article: Biomedical intelligence
Spina V, Rossi D
Swiss Med Wkly. 2019;149:w14709

“Liquid biopsy” in lymphoma types lacking leukaemic involvement refers to the accessing of tumour-specific DNA in plasma, serum or other body fluids, without the necessity of an invasive tumour biopsy.

The immune influence of a parabiosis model on tumour-bearing mice

Original article
Feng N, Luo JM, Guo X
Swiss Med Wkly. 2018;148:w14678

The occurrence and development of cancer cells in the body is a dynamic process of interaction between the immune system and the tumour cells. Whether tumour growth is promoted or suppressed in the parabiosis model is still unclear.

Diagnosis and treatment of follicular lymphoma: an update

Review article: Biomedical intelligence
Bargetzi M, Baumann R, Cogliatti S, Dietrich PY, Duchosal M, Goede J, Hitz F, Konermann C, Lohri A, Mey U, Novak U, Papachristofilou A, Stenner F, Taverna C, Zander T, Renner C
Swiss Med Wkly. 2018;148:w14635

Over the last few years, there have been many changes in the management of patients with follicular lymphoma, resulting in improvements in progression-free survival and quality of life.

Diffuse large B-cell lymphoma chemotherapy reveals a combined immunodeficiency syndrome in cartilage hair hypoplasia

Original article
Nguyen A, Martin Silva N, de Boysson H, Damaj G, Aouba A
Swiss Med Wkly. 2018;148:w14606

Cartilage hair hypoplasia is a rare autosomal recessive ribosomopathy related to a mutation in the ribonuclease mitochondrial RNA processing (RMRP) gene, which encodes the mitochondrial portion of the RNA processing endonuclease.

Verpassen Sie keinen Artikel!

close